BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent applications with the United States Patent and Trademark Office (USPTO). The first application includes claims protecting Akari’s novel immuno-oncology payload, PH1 (a novel Thailanstatin analog), and its spliceosome modulatory mechanism of action, which is expected ...

Core Insights - Akari Therapeutics has announced promising preclinical data for its novel antibody drug conjugate (ADC) payload, PH1, which targets the AR-V7 receptor linked to hormone refractory prostate cancer progression [1][2][3] Group 1: Product Development - PH1 has shown the ability to suppress AR-V7 receptor expression in a hormone-refractory metastatic castration resistant prostate cancer (mCRPC) model, indicating its potential effectiveness where current therapies fail [3] - In hormone-sensitive LnCAP cells, PH1 demonstrated single-agent benefits and additive effects when combined with existing therapies like Xtandi and Erleada, suggesting potential for first-line combination regimens [4] - The company aims to develop PH1 ADCs as either first-line therapies with ARPIs or second-line therapies for patients who have failed ARPI treatments [5] Group 2: Market Context - There is a significant unmet need for effective therapies in ARPI-resistant hormone refractory prostate cancer, as current options are limited primarily to traditional chemotherapy [2] - Current first-line therapies, including enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa), have substantial annual sales, indicating a lucrative market for effective alternatives [2] Group 3: Company Overview - Akari Therapeutics specializes in developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor and utilizing a novel PH1 payload [6] - The company’s innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific targets, enhancing its competitive edge in oncology [6][7]

Core Insights - Akari Therapeutics has filed a provisional patent application for its antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1 for cancer treatment, aiming to enhance its proprietary position in the oncology sector [1][2][4] Company Developments - The provisional patent application expands Akari's intellectual property estate and is based on the advances in understanding spliceosome modulation, which could lead to differentiated clinical outcomes for cancer patients [2][4] - Akari's lead candidate, AKTX-101, targets the Trop2 receptor and utilizes the PH1 payload, which is designed to disrupt RNA splicing in cancer cells, showing significant activity and prolonged survival in preclinical studies compared to traditional ADCs [5] Industry Context - Alternative splicing (AS) is a process that cancer cells exploit to produce protein isoforms that support tumor growth and survival, making it a critical target for cancer therapies [3] - Disrupting AS is seen as a fundamental approach to targeting various cancers, including those driven by specific spliced variants, thus positioning Akari to potentially lead in developing therapies against a wide range of cancers [3]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing next-generation spliceosome payload antibody drug conjugates (ADCs) [4] - The company utilizes an innovative ADC discovery platform to generate and optimize ADC candidates for various targets [4] Lead Product Candidate - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and employs a proprietary linker to deliver a novel PH1 payload directly into tumors [4] - PH1 is a spliceosome modulator designed to disrupt RNA splicing within cancer cells, leading to cancer cell death and activation of immune cells [4] - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, and it shows potential synergy with checkpoint inhibitors [4] Upcoming Events - Abizer Gaslightwala, President and CEO of Akari Therapeutics, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] - Management will also be available for in-person one-on-one meetings with qualified investors during the conference [2] - A video webcast of the presentation will be available on-demand starting September 5, 2025, and will be archived for 90 days [3]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [2][5] - The company has developed its first novel payload, PH1, which is a spliceosome modulator designed to disrupt RNA splicing within cells, differentiating it from current ADC payloads [5] Product Pipeline - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [5] - Preclinical studies have shown that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs [5] - The company is generating validating data on its novel payload PH1 to advance its lead asset and other undisclosed targets [5] Upcoming Events - Akari Therapeutics will participate in the Virtual Investor Closing Bell Series on September 4, 2025, where the CEO will provide a corporate overview and discuss the innovative payload platform [3][4] - Investors will have the opportunity to submit questions live during the event [3]

Core Insights - Akari Therapeutics is focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [2][4] - The company’s lead candidate, AKTX-101, utilizes a novel spliceosome modulator payload, PH1, which has shown significant preclinical activity [4] Company Overview - Akari Therapeutics is an oncology biotechnology company that has developed PH1, a spliceosome modulator designed to disrupt RNA splicing within cancer cells [4] - PH1 is differentiated from traditional ADC payloads that typically use Topoisomerase1 inhibitors or tubulin inhibitors, and it has demonstrated the ability to induce cancer cell death while activating immune cells [4] - AKTX-101 targets the Trop2 receptor on cancer cells, delivering the PH1 payload directly into tumors, and has shown prolonged survival in preclinical studies compared to traditional ADCs [4] Research and Development - The company is conducting ongoing research to further understand the effects of PH1 and its potential to disrupt key drivers of cancer cell growth [3][4] - Akari is generating validating data on PH1 to advance its lead asset and explore other undisclosed targets [4]

Core Insights - Akari Therapeutics is advancing its research on PH1, a novel spliceosome modulator that induces cancer cell death and activates the immune system to combat cancer [1][4] - The company is focused on developing antibody drug conjugates (ADCs) utilizing the PH1 payload, with ongoing preclinical studies expected to yield new data by year-end [1][3] Company Overview - Akari Therapeutics specializes in oncology biotechnology, developing innovative ADCs with a unique mechanism of action through the PH1 payload, which disrupts RNA splicing [4] - The lead candidate, AKTX-101, targets the Trop2 receptor and has shown significant activity and prolonged survival in preclinical studies compared to traditional ADCs [4] Research and Development - Ongoing research aims to explore the effects of PH1 on key oncogenic drivers such as KRAS, BRAF, and FGFR3, with preliminary data anticipated soon [2][3] - The PH1 payload has demonstrated the ability to induce cytotoxicity in cancer cells and activate immune responses, potentially leading to improved therapeutic outcomes [2][6]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [1][3] - The company has developed its first novel payload, PH1, which is a spliceosome inhibitor designed to disrupt RNA splicing within cells [3] - PH1 is differentiated from current ADC payloads that utilize Topoisomerase1 inhibitors or tubulin inhibitors, showing potential to induce cancer cell death while activating immune cells [3] Lead Candidate - Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers the PH1 payload directly into tumors [3] - In preclinical studies, AKTX-101 has demonstrated significant activity and prolonged survival compared to traditional ADCs [3] - The candidate has potential synergistic effects with checkpoint inhibitors, showing prolonged survival both as a single agent and in combination with these inhibitors [3] Recent Developments - Abizer Gaslightwala, the CEO of Akari, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference, discussing his dedication to the company and its programs [1][2] - The on-demand video webcast of the conference is available on virtualinvestorco.com and the company's website [2]

Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing novel immuno-oncology payload antibody drug conjugates (ADCs) for cancer treatment [2][4] - The company has developed its first novel payload, PH1, which is a spliceosome inhibitor designed to disrupt RNA splicing within cells, differentiating it from current ADC payloads [4] Recent Developments - Akari Therapeutics recently participated in a Virtual Investor segment where CEO Abizer Gaslightwala discussed the issuance of India Patent No. 562,919 for "Thailanstatin Analogs," which covers claims for its PH1 payload and ADC technology [3] - The PH1 payload has shown significant activity in preclinical studies, inducing cancer cell death and activating immune cells, leading to robust and durable activity [4] Product Pipeline - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors [4] - AKTX-101 has demonstrated significant activity and prolonged survival in preclinical studies compared to traditional ADCs, and it has potential synergistic effects with checkpoint inhibitors [4]